Moderna Inc (NASDAQ: MRNA) reportedly is close to signing a coronavirus vaccine deal with Israel, a testament to the validity and viability of the company's vaccine program.What Happened: The vaccine deal, which is reportedly in advanced stages of discussion, was reported by Israeli news site Ynet Sunday, quoting unnamed officials at the Israeli Health Ministry.Moderna is among the frontrunners in the race for developing a vaccine for the novel coronavirus. The Cambridge, Massachusetts-based company said last week that it has finalized the protocol for a late-stage study that will evaluate 30,000 volunteers.A preprint of animal data showed that the vaccine generated potent neutralizing activity and protected the mice from viral infection up to 13 weeks post-injection. The findings showed no safety signals. What's Next: Moderna is set to start a Phase 3 trial shortly, while the Phase 1 and 2 studies are ongoing. The company has funding from BARDA and has...
The U.S. Commerce Department and other agencies signed off on the rule change, which is awaiting publication in the Federal Register, Reuters reported, citing people familiar with the matter. The rule was sent to the Federal Register on Friday and is set to be published as early as Tuesday. U.S. Commerce Secretary Wilbur Ross confirmed the action in a statement to Reuters....
The U.S. Commerce Department and other agencies signed off on the rule change, which is awaiting publication in the Federal Register, Reuters reported, citing people familiar with the matter. The rule was sent to the Federal Register on Friday and is set to be published as early as Tuesday. U.S. Commerce Secretary Wilbur Ross confirmed the action in a statement to Reuters....
Third Avenue Management recently released its Q1 2020 Investor Letter, a copy of which you can download here. The Third Avenue Value Fund posted a return of -42.08% for the quarter, underperforming its benchmark, the MSCI World Index which returned -20.95% in the same quarter. You should check out Third Avenue Management's top 5 stock […]...
